Clinical Trials Browser

Breast Neoplasms, Neoplastic Cells, Circulating, Neoplasm Metastasis, Carcinoma, Lobular

NCT02958852 2025-09-10

ABC-SE

Phase 2 Completed

126 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT02035813 2024-06-04

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Phase 2 Completed

116 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT04771871 2022-02-18

TARMAC

Phase 2 Unknown

42 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

NCT04993014 2021-08-06

HER2Cell

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT01548677 2019-03-13

TREAT-CTC

Phase 2 Completed

1,317 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT03070002 2018-11-20

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Phase 2 Terminated

1 enrolled 6 charts

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT02602938 2015-11-13

ACABC

Phase 2 Unknown

40 enrolled

BreastGastrointestinal

Breast Neoplasms, Neoplastic Cells, Circulating, Colorectal Neoplasms

NCT00429182 2013-04-10

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Phase 2 Completed

32 enrolled 6 charts

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

Clinical Trials

Biomarkers to Detect Endocrine Therapy Resistance

ABC-SE

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

TARMAC

HER2Cell

TREAT-CTC

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

ACABC

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer